A retrospective real-world single-arm study evaluating the efficacy and safety of neoadjuvant chemotherapy in patients with selected limited-stage small-cell lung cancer.

BACKGROUND

With the advancement of surgical techniques and the introduction of neoadjuvant therapies, the risk of recurrence or distant metastases has been significantly decreased for non-small-cell lung cancer (non-SCLC) after surgery. In recent years, the application of these advanced techniques and therapies in SCLC has also shown promise. This study aims to explore the efficacy and safety of neoadjuvant chemotherapy combined with surgery in selected limited-stage SCLC (LS-SCLC).

METHODS

In this retrospective, single-arm clinical trial, we conducted a thorough review of electronic medical records from the Shanghai Pulmonary Hospital between December 2015 and December 2022. Patients with a pathological diagnosis of SCLC who underwent neoadjuvant chemotherapy followed by radical surgery were enrolled. Baseline demographic and clinical characteristics, specifics of neoadjuvant therapy and surgery, survival outcomes, and safety profiles of included patients were systematically collected and analyzed.

RESULTS

A total of 47 patients [7 (14.89%) females and 40 (85.11%) males; median age 61.00 years, interquartile range (IQR), 55.50-67.50 years] were enrolled. The disease control rate was 100%, with an objective response rate of 70.21% and a downstaging rate of 65.9%. The percentage of patients with a complete pathological response (CPR) and major pathological response (MPR) was 10.64% (5/47) and 12.77% (6/47, excluding CPR), respectively. In subgroups stratified by baseline demographic and clinical characteristics, the MPR rate showed no significant differences, yet a trend toward higher MPR was observed among smoking patients. At the data cutoff (October 2, 2024), the median follow-up period was 35.367 months [IQR, 26.367 months-not reached (NR)]. The median event-free survival (EFS) was 16.27 months [95% confidence interval (CI): 12.20-30.53] and the median overall survival (OS) was NR, with 2-, 3-, and 4-year survival rates of 79.96% (95% CI: 68.36-93.52%), 71.39% (95% CI: 57.12-89.22%), and 64.90% (95% CI: 48.52-86.82%), respectively. The stratified analysis revealed that patients achieving an MPR and those undergoing postoperative adjuvant radiotherapy exhibited longer EFS and OS. Treatment-related adverse events of grade 3-4 were observed in 21.28% of patients, with the most frequent occurrences being a decrease in neutrophil count (12.77%), followed by a decrease in platelet count (8.51%), and a decrease in white blood cell count (4.26%).

CONCLUSIONS

Neoadjuvant chemotherapy combined with surgery could be a potential treatment strategy for LS-SCLC, with a high proportion of patients achieving an MPR, and manageable safety profile, that did not compromise surgical resection. Further prospective clinical trials are warranted to delineate the benefits of neoadjuvant chemotherapy and optimize LS-SCLC treatment.